{"id":52329,"date":"2024-10-31T09:27:40","date_gmt":"2024-10-31T09:27:40","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=52329"},"modified":"2024-10-31T09:27:40","modified_gmt":"2024-10-31T09:27:40","slug":"sugemalimab-approved-to-treat-adult-patients-with-non-small-cell-lung-cancer","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/sugemalimab-approved-to-treat-adult-patients-with-non-small-cell-lung-cancer\/52329\/","title":{"rendered":"Sugemalimab approved to treat adult patients with non-small cell lung cancer\u202f\u202f\u202f\u202f"},"content":{"rendered":"

Non-small cell lung cancer is the most common form of lung cancer, accounting for around 80 to 85 out of 100 cases.<\/h2>\n

Non-small cell lung cancer can be one of three types: squamous cell carcinoma, adenocarcinoma or large-cell carcinoma.<\/p>\n

Now, the Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the medicine sugemalimab (Eqjubi) to treat adult patients with non-small cell lung cancer.<\/p>\n

Sugemalimab is a monoclonal antibody (a protein designed to recognise and attach to a specific target in the body).<\/p>\n

It works by attaching to a target called programmed death-ligand 1 (PD-L1). Cancer cells with PD-L1 may switch off some immune system cells.<\/p>\n

By blocking PD-1, sugemalimab stops cancer, switches off immune cells, and increases the immune system\u2019s ability to kill cancer cells<\/a>.<\/p>\n

Sugemalimab found to be most effective treatment for non-small cell lung cancer<\/h3>\n

Sugemalimab is given to the patient in a hospital or clinic under the supervision of an experienced doctor.<\/p>\n

The patient\u2019s doctor will give them sugemalimab through an infusion (drip) into a vein over 60 minutes every three weeks.<\/p>\n

Clinical trials showed that sugemalimab in combination with platinum-based chemotherapy was more effective than placebo (a dummy treatment) in patients with Stage 4 metastatic lung cancer.<\/p>\n

The main measure of effectiveness was survival without worsening (progression) of small-cell lung cancer.<\/p>\n

Patients who had sugemalimab treatment lived, on average, nine months without the disease getting worse, compared with 4.9 months for patients who did not receive sugemalimab.<\/p>\n

Julian Beach, MHRA Interim Executive Director of Healthcare Quality and Access, explained, \u201cEnabling safe access to high-quality, safe, and effective medicines is a key priority for us.<\/p>\n

\u201cWe\u2019re assured that the appropriate regulatory standards of safety, quality and effectiveness for the approval of this new formulation have been met.\u201d<\/p>\n

Side effects of sugemalimab<\/h3>\n

During clinical studies, common side effects of patients will small-cell lung cancer included:<\/p>\n